Prognostic value of CRT, HSP70, and HP90 exposure in patients with AML. (A-C) RFS and OS among 50 patients with AML stratified in 2 groups based on median percentage of circulating ecto-CRT⁺ (A), ecto-HSP70⁺ (B), or ecto-HSP90⁺ (C) blasts measured prior to induction chemotherapy. Patients at risk are reported. The Wilcoxon test was employed to assess statistical significance. (D-E) Overall survival of 30 patients with AML from our cohort (D) and 173 patients with AML from the TCGA public database (E) stratified in 2 groups based on median CALR mRNA levels. Patients at risk are reported.